58 related articles for article (PubMed ID: 9816272)
1. Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity.
Barnes MN; Deshane JS; Siegal GP; Alvarez RD; Curiel DT
Clin Cancer Res; 1996 Jul; 2(7):1089-95. PubMed ID: 9816272
[TBL] [Abstract][Full Text] [Related]
2. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines.
Deshane J; Loechel F; Conry RM; Siegal GP; King CR; Curiel DT
Gene Ther; 1994 Sep; 1(5):332-7. PubMed ID: 7584099
[TBL] [Abstract][Full Text] [Related]
3. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody.
Deshane J; Cabrera G; Grim JE; Siegal GP; Pike J; Alvarez RD; Curiel DT
Gynecol Oncol; 1995 Oct; 59(1):8-14. PubMed ID: 7557620
[TBL] [Abstract][Full Text] [Related]
4. Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis.
Deshane J; Grim J; Loechel S; Siegal GP; Alvarez RD; Curiel DT
Cancer Gene Ther; 1996; 3(2):89-98. PubMed ID: 8729907
[TBL] [Abstract][Full Text] [Related]
5. Intracellular expression of the anti-erbB-2 sFv N29 fails to accomplish efficient target modulation.
Grim JE; Siegal GP; Alvarez RD; Curiel DT
Biochem Biophys Res Commun; 1998 Sep; 250(3):699-703. PubMed ID: 9784409
[TBL] [Abstract][Full Text] [Related]
6. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial.
Alvarez RD; Barnes MN; Gomez-Navarro J; Wang M; Strong TV; Arafat W; Arani RB; Johnson MR; Roberts BL; Siegal GP; Curiel DT
Clin Cancer Res; 2000 Aug; 6(8):3081-7. PubMed ID: 10955787
[TBL] [Abstract][Full Text] [Related]
7. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
[TBL] [Abstract][Full Text] [Related]
8. Regulation of multiple tumor microenvironment markers by overexpression of single or paired combinations of ErbB receptors.
Alaoui-Jamali MA; Song DJ; Benlimame N; Yen L; Deng X; Hernandez-Perez M; Wang T
Cancer Res; 2003 Jul; 63(13):3764-74. PubMed ID: 12839972
[TBL] [Abstract][Full Text] [Related]
9. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
10. Suppression of the c-erbB-2 gene product decreases transformation abilities but not the proliferation and secretion of proteases of SK-OV-3 ovarian cancer cells.
Wiechen K; Karaaslan S; Turzynski A; Dietel M
Br J Cancer; 1999 Nov; 81(5):790-5. PubMed ID: 10555747
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptors for stem cell based immunotherapy.
Badowski MS; Zhang T; Tsang TC; Harris DT
J Exp Ther Oncol; 2009; 8(1):53-63. PubMed ID: 19827271
[TBL] [Abstract][Full Text] [Related]
12. [Effect of RNAi-mediated gene silencing of C-erbB-2 on proliferation of lung adenocarcinoma cell line calu-3].
Ren SH; Zhang W; Qu P; Liu Y; Wang JW; Zhang L
Ai Zheng; 2005 Oct; 24(10):1173-8. PubMed ID: 16219128
[TBL] [Abstract][Full Text] [Related]
13. E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs.
Zhou Z; Jia SF; Hung MC; Kleinerman ES
Cancer Res; 2001 Apr; 61(8):3394-8. PubMed ID: 11309298
[TBL] [Abstract][Full Text] [Related]
14. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
Rusnak DW; Affleck K; Cockerill SG; Stubberfield C; Harris R; Page M; Smith KJ; Guntrip SB; Carter MC; Shaw RJ; Jowett A; Stables J; Topley P; Wood ER; Brignola PS; Kadwell SH; Reep BR; Mullin RJ; Alligood KJ; Keith BR; Crosby RM; Murray DM; Knight WB; Gilmer TM; Lackey K
Cancer Res; 2001 Oct; 61(19):7196-203. PubMed ID: 11585755
[TBL] [Abstract][Full Text] [Related]
15. Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3.
Jia LT; Zhang LH; Yu CJ; Zhao J; Xu YM; Gui JH; Jin M; Ji ZL; Wen WH; Wang CJ; Chen SY; Yang AG
Cancer Res; 2003 Jun; 63(12):3257-62. PubMed ID: 12810656
[TBL] [Abstract][Full Text] [Related]
16. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.
Ueno NT; Bartholomeusz C; Herrmann JL; Estrov Z; Shao R; Andreeff M; Price J; Paul RW; Anklesaria P; Yu D; Hung MC
Clin Cancer Res; 2000 Jan; 6(1):250-9. PubMed ID: 10656456
[TBL] [Abstract][Full Text] [Related]
17. Luteinizing hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and invasion in ovarian cancer cells.
Warrenfeltz SW; Lott SA; Palmer TM; Gray JC; Puett D
Mol Cancer Res; 2008 Nov; 6(11):1775-85. PubMed ID: 19010824
[TBL] [Abstract][Full Text] [Related]
18. Dual effect of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cells.
You XL; Yen L; Zeng-Rong N; Al Moustafa AE; Alaoui-Jamali MA
Oncogene; 1998 Dec; 17(24):3177-86. PubMed ID: 9872333
[TBL] [Abstract][Full Text] [Related]
19. Expression of activated c-erbB-2 oncogene induces sensitivity to cisplatin in human gallbladder adenocarcinoma cells.
Boudny V; Murakami Y; Nakano S; Niho Y
Anticancer Res; 1999; 19(6B):5203-6. PubMed ID: 10697535
[TBL] [Abstract][Full Text] [Related]
20. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
